Intellectus Partners LLC Makes New $284,000 Investment in CRISPR Therapeutics AG $CRSP

Intellectus Partners LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,845 shares of the company’s stock, valued at approximately $284,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. ARK Investment Management LLC raised its holdings in shares of CRISPR Therapeutics by 13.3% during the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after purchasing an additional 1,192,336 shares during the period. B & T Capital Management DBA Alpha Capital Management bought a new stake in CRISPR Therapeutics in the 1st quarter valued at about $416,000. IVC Wealth Advisors LLC bought a new stake in CRISPR Therapeutics in the 2nd quarter valued at about $225,000. Koss Olinger Consulting LLC lifted its position in CRISPR Therapeutics by 29.8% in the 2nd quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock valued at $2,052,000 after purchasing an additional 9,685 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after purchasing an additional 33,711 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRSP has been the topic of several recent research reports. Chardan Capital reiterated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada lifted their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 5th. Bank of America lifted their price objective on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Ten research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average target price of $72.59.

CRISPR Therapeutics Trading Down 3.2%

CRISPR Therapeutics stock opened at $61.97 on Tuesday. The stock has a market cap of $5.64 billion, a price-to-earnings ratio of -11.41 and a beta of 1.89. The company’s 50-day moving average price is $62.69 and its two-hundred day moving average price is $52.72. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s quarterly revenue was up 72.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.49) EPS. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. The trade was a 16.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares in the company, valued at $5,554,573.20. This represents a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 56,213 shares of company stock worth $3,810,458 in the last ninety days. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.